Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation-Reference-Cited by-同舟云学术

Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Published:2023-04-11 Issue:7 Volume:58 Page:784-790
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Abou Dalle Iman^ORCID,Labopin Myriam^ORCID,Kröger Nicolaus^ORCID,Schroeder Thomas^ORCID,Finke Jürgen^ORCID,Stelljes Matthias,Neubauer Andreas,Blaise Didier,Yakoub-Agha Ibrahim,Salmenniemi Urpu,Forcade Edouard,Itäla-Remes Maija,Dreger Peter^ORCID,Bug Gesine,Passweg Jakob,Heuser Michael^ORCID,Choi Goda,Brissot Eolia^ORCID,Giebel Sebastian,Nagler Arnon,Ciceri Fabio^ORCID,Bazarbachi Ali^ORCID,Mohty Mohamad^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-023-01961-1.pdf

Reference26 articles.

1. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47. https://doi.org/10.1182/blood-2016-08-733196.

2. Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138:2753–67. https://doi.org/10.1182/blood.2021013626.

3. Schuurhuis GJ, Heuser M, Freeman S, Bene MC, Buccisano F, Cloos J, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131:1275–91. https://doi.org/10.1182/blood-2017-09-801498.

4. Nagler A, Baron F, Labopin M, Polge E, Esteve J, Bazarbachi A, et al. Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. Bone Marrow Transpl. 2021;56:218–24. https://doi.org/10.1038/s41409-020-01005-y.

5. Buckley SA, Wood BL, Othus M, Hourigan CS, Ustun C, Linden MA, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica. 2017;102:865–73. https://doi.org/10.3324/haematol.2016.159343.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Place de l’allogreffe dans les leucémies aiguës myéloblastiques et syndromes myélodysplasiques de très haut risque (SFGM-TC);Bulletin du Cancer;2024-09

2. Early blast clearance during sequential conditioning prior to allogeneic stem cell transplantation in patients with acute myeloid leukaemia;British Journal of Haematology;2024-06-04

3. Allogeneic Stem Cell Transplantation in Refractory Acute Myeloid Leukaemia;Cells;2024-04-26

4. Allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia not in remission;Leukemia;2023-12-21

5. Autologous stem cell transplantation in adult patients with intermediate-risk acute myeloid leukemia in first complete remission and no detectable minimal residual disease. A comparative retrospective study with haploidentical transplants of the global committee and the ALWP of the EBMT;Bone Marrow Transplantation;2023-08-28